CircZNF800 in CRC cells was confirmed by RNase R resistance (Fig. 1B) and significantly longer half-life than the host transcript ZNF800 on actinomycin D challenge (Fig. 1C) in the two CRC cell lines tested. Here, ZNF800 is linked to colorectal carcinoma.